Solar X-ray and EUV imager on board the FY-3E satellite.

The solar X-ray and Extreme Ultraviolet Imager (X-EUVI), developed by the Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy of Sciences (CIOMP), is the first space-based solar X-ray and Extreme ultraviolet (EUV) imager of China loaded on the Fengyun-3E (FY-3E) satellite supported by the China Meteorological Administration (CMA) for solar observation. Since started work on July 11, 2021, X-EUVI has obtained many solar images. The instrument employs an innovative dual-band design to monitor a much larger temperature range on the Sun, which covers 0.6-8.0 nm in the X-ray region with six channels and 19.5 nm in the EUV region. X-EUVI has a field of view of 42', an angular resolution of 2.5″ per pixel in the EUV band and an angular resolution of 4.1″ per pixel in the X-ray band. The instrument also includes an X-ray and EUV irradiance sensor (X-EUVS) with the same bands as its imaging optics, which measures the solar irradiance and regularly calibrates the solar images. The radiometric calibration of X-EUVS on the ground has been completed, with a calibration accuracy of 12%. X-EUVI is loaded on the FY-3E satellite and rotates relative to the Sun at a uniform rate. Flat-field calibration is conducted by utilizing successive rotation solar images. The agreement between preliminarily processed X-EUVI images and SDO/AIA and Hinode/XRT images indicates that X-EUVI and the data processing algorithm operate properly and that the data from X-EUVI can be applied to the space weather forecast system of CMA and scientific investigations on solar activity.

Comparative study of the therapeutic effect between BTD and BCD for new multiple myeloma / 解放军医学杂志

Objective To investigate the clinical efficacy and safety of bortezomib-based chemotherapy regimen [BTD chemotherapy regimen (bortezomib and thalidomide combined with dexamethasone) and BCD chemotherapy regimen (bortezomib and cyclophosphamide combined with dexamethasone)] in the treatment of new multiple myeloma (MM). Methods From May 2015 to May 2019, 80 newly diagnosed MM patients hospitalized in the Department of Hematology of Sanya Central Hospital were divided into BTD group (n=40) and BCD group (n=40). Patients in BTD group were given BTD chemotherapy regimen, and BCD group patients were given BCD chemotherapy regimen. Clinical efficacy, changes in myeloma markers [serum M protein, serum free light chain (κ-λ), immunofixation electrophoresis, β2 microglobulin, bone marrow plasma cells] and adverse reactions were evaluated in the two groups after 4 courses of treatment. Overall survival (OS) and progression-free survival (PFS) in the two groups were evaluated at follow-up period. Results The overall response rate (ORR) of the BTD group was significantly higher than that of the BCD group [95.0%(38/40) vs. 75.0%(30/40)], the difference was statistically significant (P0.05). Conclusion In the bortezomib-based chemotherapy regimen, the efficacy of BTD group is significantly better than that of BCD group, which could effectively reduce the indexes of myeloma, and the adverse reactions are lower, but there would be no significant difference in OS and PFS between the two groups.

Berberine ameliorates CCl4­induced liver injury in rats through regulation of the Nrf2­Keap1­ARE and p53 signaling pathways.

Berberine (BBR) is an isoquinoline alkaloid, reported to have multiple pharmacological functions. However, its effects against CCl4­induced oxidative damage remain poorly studied. Therefore, the present study investigated the protective action of BBR, and its antioxidant mechanisms, against CCl4­induced liver injury in rats. A total of 48 rats were randomly arranged into six groups: Control; model; positive control (PC); BBR low­dose (BL); BBR middle­dose (BM); and BBR high­dose (BH). The BL, BM and BH animals received BBR (5, 10 and 15 mg/kg by weight, respectively) orally for 7 consecutive days. Rats in the PC group were given silymarin (150 mg/kg), and the control and model groups were administered distilled water orally. At the end of the experiment, blood samples and livers were collected. To measure the liver biochemical indices, the reactive oxygen species (ROS) generation and the expression levels of related genes and protein, the following methods were used: An automatic biochemical analyzer; flow cytometry; spectrophotometry; reverse transcription­quantitative PCR; western blotting; and hematoxylin and eosin staining. The results revealed that BBR significantly decreased the serum levels of alanine transaminase, aspartate transaminase and alkaline phosphatase, and increased those of glutathione and superoxide dismutase, but decreased malondialdehyde activity in hepatic tissue, and significantly decreased the reactive oxygen species level in hepatocytes. In hepatic tissue, the expressions of nuclear factor erythroid 2­related factor 2 (Nrf2), kelch­like ECH­associated protein 1 (Keap-1), NAD(P)H quinone dehydrogenase 1 (NQO-1), heme oxygenase 1 (HO­1), Bcl­2 and Bcl­xL mRNA, and HO­1 protein were elevated, and the expression of p53 mRNA was decreased, particularly in the BH group (15 mg/kg). In conclusion, BBR exerts a protective action against CCl4­induced acute liver injury in rats via effectively regulating the expression of Nrf2­Keap1­antioxidant responsive element­related genes and proteins, and inhibiting p53 pathway­mediated hepatocyte apoptosis.